Surgery Partners (SGRY) Proxy filing summary

Executive summary

• Amended merger agreement raises cash consideration to $25.00 per share; if stockholder approval is obtained but closing has not occurred by March 1, 2027, monthly payments accrue at 10% annually, up to $1.61 per share by the October 23, 2027 outside date.

• Maximum per-share consideration is $26.61, implying enterprise value of up to approximately $6.0 billion; closing remains expected in Q1 2027, subject to stockholder and regulatory approvals and other conditions.

• The amendment followed an unsolicited third-party proposal of $28.00 per share; the Special Committee and Board chose the revised HealthSpan Partners transaction, citing timing, regulatory risk and protections.

Voting matters and shareholder proposals

• The Board reaffirmed its recommendation that stockholders approve the merger at a special meeting; a definitive proxy statement and Schedule 13E-3 are to be filed and distributed.

• Bain Capital, collectively holding approximately 39% of outstanding shares, remains bound by its support agreement to vote its shares for the merger.

Board of directors and corporate governance

• An independent, disinterested Special Committee led negotiations and unanimously found the $28.00 third-party proposal was not a Superior Proposal, considering the amended transaction and its comparative risks.

• The Board approved the amendment following the Special Committee’s recommendation, determining the revised terms represented the best transaction for stockholders.